This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Update on Interstitial Lung Disease: A Path to Earlier Diagnosis and Better Outcomes

Update on Interstitial Lung Disease: A Path to Earlier Diagnosis and Better Outcomes

Format

Webcast

Time to Complete

1 hour

Released

October 29, 2018

Expires

October 29, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by Paradigm Medical Communications, LLC.

Commercial Supporter

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

Interstitial lung disease (ILD) presents challenges for pulmonologists, radiologists, and pathologists, who must discern among more than 100 other potential ILDs and non-ILD mimickers via scrupulous testing and multidisciplinary collaboration to arrive at an accurate and timely diagnosis. Early detection has become more critical than ever, with the US Food and Drug Administration’s (FDA) first-ever approval of treatments (antifibrotics) for idiopathic pulmonary fibrosis (IPF), a fatal and relentlessly progressive fibrosing ILD. While these agents offer an unprecedented opportunity to slow IPF disease progression, guidance on the practical aspects of their use, including when to start prescribing them, is needed. Research is underway to determine whether nintedanib, an antifibrotic agent indicated for IPF, could also benefit patients with progressive fibrosing (PF)-ILD or systemic sclerosis ILD (SSc-ILD), a connective tissue disease-related ILD (CTD-ILD), for which nintedanib was granted orphan drug status in 2016. With new data emerging, and expanded indications possible soon, education on ILD management is a topic of timeliness and relevance to many healthcare professionals.

Table of Contents

  • Introduction: The Challenges and Importance of Early ILD Diagnosis
  • Evaluating the Nonspecific Symptoms of ILD: Guideline-based Strategies for Earlier Detection
  • Comprehensive Care of the IPF Patient: Therapeutic Options and Shared Decision-making

Intended Audience

This activity has been designed to address the educational needs of pulmonologists, radiologists, and pathologists. The activity may also benefit primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other allied healthcare providers who care for patients with interstitial lung disease.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Evaluate patients with symptoms of interstitial lung disease according to guideline-based algorithms to distinguish between idiopathic pulmonary fibrosis and connective tissue disease-related interstitial lung disease.
  • Individualize antifibrotic therapy for appropriate patients with idiopathic pulmonary fibrosis, based on current evidence.
  • Outline evidence-based information about interstitial lung disease course and treatment to share with patients at the time of diagnosis.

Conflict Of Interest Disclosure Policy

Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Faculty

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Faculty Presenter
Mark J. Hamblin, MD, FCCP

Assistant Professor
Director of KU ILD & Rare Lung Disease Clinic
Division of Pulmonary and Critical Care Medicine
University of Kansas Health Care System
Kansas City, KS

Dr. Hamblin discloses the following:
Grant/Research Support: Biogen; Boehringer Ingelheim Pharmaceuticals, Inc; FibroGen, Inc.; Genentech, Inc.; Global Blood Therapeutics, Inc.; Promedior, Inc.
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc

Steering Committee
David J. Lederer, MD, MS (Chair)

Associate Professor of Medicine and Epidemiology
Division of Pulmonary, Allergy, and Critical Care Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY

Dr. Lederer discloses the following:
Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc; FibroGen, Inc.
Retained Consultant: FibroGen, Inc.; Galapagos NV; Global Blood Therapeutics, Inc.; Roche; Sanofi Genzyme; Veracyte, Inc.

Erica L. Herzog, MD, PhD
Associate Professor
Department of Internal Medicine
Section of Pulmonary, Critical Care, and Sleep Medicine
Director, Interstitial Lung Disease Center of Excellence
Yale School of Medicine
New Haven, CT

Dr. Herzog discloses the following:
Grant/Research Support: Bristol-Myers Squibb Company; sanofi-aventis U.S. LLC
Retained Consultant: Boehringer Ingelheim Pharmaceuticals, Inc
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc

Rebecca C. Keith, MD
Assistant Professor
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Interstitial Lung Disease Program
Sarcoidosis Program
Autoimmune Lung Center
National Jewish Health
Denver, CO

Dr. Keith discloses the following:
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.

Contributing Faculty
Jay S. Leb, MD

Assistant Professor of Radiology
Department of Radiology
Columbia University Medical Center
New York, NY

Dr. Leb discloses the following:
Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.

Julie Porcelli, MSN, RN, CNL
Program Coordinator
Division of Pulmonary, Allergy and Critical Care Medicine
Columbia University Medical Center
New York, NY

Ms. Porcelli discloses the following:
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.

Anjali Saqi, MD, MBA
Professor
Department of Pathology and Cell Biology
Columbia University Medical Center
New York, NY

Dr. Saqi discloses the following:
Grant/Research Support: Columbia-Coulter Translational Research Partnership; FAR-ILD
Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.
Retained Consultant: Boston Scientific Corporation; Genentech, Inc.

Patient Faculty
Robert Byrnes

Parsippany, NJ

Mr. Byrnes has no financial relationships to disclose.

Accredited Provider Disclosure

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Instructions

To receive a CME certificate of participation, participants must:
  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pre-activity assessment.
  • View the online activity in its entirety.
  • Complete and submit the online post-activity assessment and evaluation.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-activity assessment and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

There is no fee required for participation in this activity.

Privacy Policy

Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

Terms of Use and Privacy Policy
Paradigm Medical Communications, LLC, is committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC, to continuously improve the learning experience.

Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.

myCME privacy policy

Technical Requirements

This certified CME activity is designed using HTML5 video. As you navigate using the supplied controls, the slides will sync to the speaker.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Copyright

© 2018 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Add to Queue